Hereditary Hemorrhagic Telangiectasia (HHT) research hub

A Phase 1/2, First-in-Human, Multicenter, Ascending Single-Dose and Multi-Dose Study to Assess the Safety of DIAG723, a Novel Bispecific ALK-1 and BMPRII Agonist Antibody in Adult Patients with Hereditary Hemorrhagic Telangiectasia (DIAMOND trial)

This clinical trial tests an experimental medicine called DIAG723 for adults with hereditary haemorrhagic telangiectasia (HHT). Researchers want to find out if the treatment is safe, how the body handles it, and whether it can help reduce frequent nosebleeds and improve blood counts in people living with this condition.